HSV-2 remains a massive, fast moving public health reality with about 25.6 million new HSV-2 cases globally in 2020 and roughly 491 million adults aged 15 to 49 living with the infection. Even when testing seems straightforward, the performance flips depending on the method, with lesion PCR often hitting 95 to 100% sensitivity while routine serology can miss early infections and NAAT can detect DNA in atypical lesions where symptoms mislead. This post brings the most useful HSV-2 statistics together so you can see exactly where each test is strongest, and where it can quietly underperform.
Key Takeaways
- HSV-2 Type-Specific IgG serology detects 96-100% of infections after 3 months
- PCR of lesion swabs has sensitivity 95-100%, specificity 95-99% for HSV-2
- Western blot confirms HSV-2 in 99% of type-discordant sera from ELISA
- Globally, approximately 491 million people aged 15-49 years were living with HSV-2 infection in 2020, corresponding to 13% prevalence
- In the United States, 11.9% of persons aged 14–49 years are infected with HSV-2 based on seroprevalence data from 2015-2016
- HSV-2 seroprevalence among women in the US is 15.9% compared to 8.2% in men aged 14-49 (2015-2016 NHANES)
- Initial genital herpes outbreaks occur within 2-12 days of exposure in 90% of cases
- 80-90% of HSV-2 infections are asymptomatic or unrecognized at acquisition
- Painful vesicular lesions on genitals last 7-10 days in primary HSV-2 infection
- The probability of HSV-2 transmission from infected male to female per act of vaginal sex is 10% without condoms
- Female-to-male HSV-2 transmission risk per vaginal sex act is approximately 4-5%
- Condom use reduces HSV-2 transmission by 30-50% in discordant couples
- Acyclovir 400mg three times daily for 7-10 days shortens primary outbreak duration by 2-4 days
- Suppressive valacyclovir 500mg daily reduces recurrences by 70-80% in frequent shedders
- Episodic acyclovir 800mg three times daily x 2 days aborts 40% of prodromal outbreaks
HSV-2 testing is highly accurate, with IgG and PCR leading detection of common silent infections.
Related reading
01 · Category
Diagnosis and Testing25 stats
01
HSV-2 Type-Specific IgG serology detects 96-100% of infections after 3 months
02
PCR of lesion swabs has sensitivity 95-100%, specificity 95-99% for HSV-2
03
Western blot confirms HSV-2 in 99% of type-discordant sera from ELISA
04
NAAT (nucleic acid amplification test) detects HSV DNA in 70-90% of atypical lesions
05
IgM antibodies unreliable for acute HSV-2 diagnosis, false positives 50-70%
06
Type-specific glycoprotein G-based assays (HerpeSelect) sensitivity 91-97% at 12 weeks post-infection
07
Viral culture sensitivity only 50% by day 3 of lesion, <20% after day 5
08
CSF PCR positive in 95% of HSV-2 Mollaret's meningitis cases
09
Biokit HSV-2 rapid test has 92% sensitivity, 98% specificity in high-prevalence settings
10
Focus ELISA index value >3.5 indicates true HSV-2 positivity in 98% cases
11
Point-of-care HSV-2 tests like Dual HIV/syphilis/HSV-2 have 93% accuracy
12
Tzanck smear shows multinucleated giant cells in 60-70% of vesicular lesions
13
Seroconversion to HSV-2 IgG occurs in 50% by 3 weeks, 70% by 6 weeks post-primary infection
14
HSV-2 DNA PCR in genital swabs detects subclinical shedding with 95% specificity
15
Cross-reactivity in type-common assays leads to 15-20% false HSV-2 positives from HSV-1
16
Neonatal HSV diagnosed by surface culture/PCR in 90% cases within first 4 weeks
17
Euroimmun HSV-2 IgG ELISA specificity 97.8%, sensitivity 98.2% vs Western blot
18
Self-collected vaginal swabs for HSV PCR have 90% concordance with clinician swabs
19
HSV-2 resistance to acyclovir detected in <1% immunocompetent, 5% immunocompromised via genotypic testing
20
Routine HSV serology not recommended for asymptomatic adults per CDC (low PPV <10% in low prevalence)
21
Real-time PCR distinguishes HSV-1/2 with 99% accuracy, detects <100 copies/mL
22
Liaison HSV-2 IgG assay sensitivity 96%, specificity 99% in pregnant women
23
False-negative serology in early infection (<12 weeks) occurs in 30% with glycoprotein G assays
24
HSV-2 IgG avidity testing helps date infection (<0.8 low avidity indicates recent)
25
Direct fluorescent antibody (DFA) test sensitivity 88%, faster than culture
Interpretation
Diagnosis and Testing Interpretation
When interpreting HSV-2 diagnostics, the wise clinician knows that while a Western blot is the gold standard serology, a PCR swab from a fresh lesion is your best immediate shot, but you'll need to wait a full three months for the antibodies to tell their true, and often surprising, story.
02 · Category
Prevalence and Epidemiology30 stats
01
Globally, approximately 491 million people aged 15-49 years were living with HSV-2 infection in 2020, corresponding to 13% prevalence
02
In the United States, 11.9% of persons aged 14–49 years are infected with HSV-2 based on seroprevalence data from 2015-2016
03
HSV-2 seroprevalence among women in the US is 15.9% compared to 8.2% in men aged 14-49 (2015-2016 NHANES)
04
In sub-Saharan Africa, HSV-2 prevalence among adults aged 15-49 reaches up to 50% in some populations
05
Lifetime risk of acquiring HSV-2 for women is 1 in 5, while for men it is 1 in 9 in the general population
06
HSV-2 prevalence increases with age, peaking at 25.6% in persons aged 40-49 in the US (2015-2016)
07
In Europe, HSV-2 seroprevalence is around 5-10% in the general adult population, varying by country
08
Among pregnant women in the US, HSV-2 seroprevalence is approximately 20-25%
09
In India, HSV-2 prevalence among antenatal clinic attendees is 12-42% depending on region
10
HSV-2 infection rates are higher in non-Hispanic Black populations at 34.6% vs 8.1% in non-Hispanic Whites (US 2015-2016)
11
Globally, 67% of people under 50 are infected with HSV-1, but HSV-2 accounts for 12% in 15-49 year olds
12
In Brazil, HSV-2 seroprevalence is 15.6% among women aged 15-49
13
HSV-2 prevalence among men who have sex with men (MSM) is 20-30% in high-income countries
14
In South Africa, HSV-2 prevalence in women aged 15-24 is 25.8%
15
US incidence of HSV-2 is estimated at 700,000 new cases annually among 14-49 year olds
16
HSV-2 seroprevalence in Asia-Pacific region averages 10-15% in adults
17
Among female sex workers in low-income countries, HSV-2 prevalence exceeds 50%
18
In Canada, HSV-2 prevalence is 14% in women and 8% in men aged 14-59
19
HSV-2 infection correlates with HIV prevalence, with odds ratio of 2.7-3.6 in discordant couples
20
In Australia, HSV-2 seroprevalence is 12% in adults aged 20-29, rising to 23% in 50-59
21
Global HSV-2 incidence in 2020 was 25.6 million new cases among 15-49 year olds
22
In the UK, HSV-2 prevalence is about 10% in adults under 50
23
HSV-2 seroprevalence among US military personnel is 5.3%
24
In China, HSV-2 prevalence among pregnant women is 6.8-9.2%
25
Among adolescents in the US, HSV-2 prevalence is 1.4% in 14-19 year olds (2015-2016)
26
HSV-2 prevalence in Latin America averages 15-20% in women
27
In Kenya, HSV-2 seroprevalence in fishermen is 54%
28
US HSV-2 prevalence declined from 16.0% in 1999-2000 to 11.9% in 2015-2016
29
Globally, 205 million people aged 15-49 have symptomatic HSV-2 episodes annually
30
In Japan, HSV-2 seroprevalence is low at 2-5% in the general population
Interpretation
Prevalence and Epidemiology Interpretation
This vast and varied map of HSV-2 prevalence paints a clear, sobering picture: a staggeringly common virus whose distribution is unjustly dictated by geography, gender, and systemic inequities, not simply by individual behavior.
03 · Category
Symptoms and Clinical Manifestations25 stats
01
Initial genital herpes outbreaks occur within 2-12 days of exposure in 90% of cases
02
80-90% of HSV-2 infections are asymptomatic or unrecognized at acquisition
03
Painful vesicular lesions on genitals last 7-10 days in primary HSV-2 infection
04
Prodromal symptoms like tingling or burning precede outbreaks in 50% of recurrent episodes
05
Primary HSV-2 infection causes constitutional symptoms (fever, malaise) in 40-70% of women
06
Recurrent outbreaks occur 4-6 times per year on average, decreasing over time
07
Aseptic meningitis complicates 36% of primary HSV-2 genital herpes cases in women
08
Urinary retention due to sacral radiculitis occurs in 10-20% of primary episodes
09
Extragenital lesions (buttocks, thighs) occur in 20-30% of HSV-2 outbreaks
10
Neuralgia or dysesthesia persists >1 month in 10-15% of primary infections
11
HSV-2 proctitis in MSM presents with severe anorectal pain, discharge in 70% cases
12
Lymphadenopathy accompanies 60-80% of primary genital HSV-2 infections
13
Autonomic dysfunction (e.g., constipation) in 15% of primary HSV-2 cases
14
Recurrent HSV-2 episodes last 3-7 days, milder than primary (pain score 2-3 vs 6-7)
15
Erythema multiforme triggered by HSV-2 in 10% of recurrent cases
16
Neonatal HSV-2 infection presents with skin/eye/mouth disease in 45%, CNS in 30%, disseminated in 25%
17
Chronic neuropathic pain affects 5-10% long-term after HSV-2 infection
18
HSV-2 cervicitis causes abnormal Pap smears in 20-30% of infected women
19
Frequency of recurrences: 80% have ≥1/year, 20% have >12/year initially
20
Vesicles ulcerate within 48 hours, crust over by day 7-10 in typical outbreaks
21
Flu-like symptoms in primary infection: fever in 40%, myalgia 50%
22
Sacral paresthesias in 20% of recurrences
23
HSV-2 associated with 10-20% of idiopathic urethritis cases in men
24
Lesion healing delayed >14 days in 10% of primary episodes without treatment
25
Psychological impact: 25% report significant anxiety/depression post-diagnosis
Interpretation
Symptoms and Clinical Manifestations Interpretation
This bewildering virus, which announces itself with such theatrical flair in a few, masterfully hides in the shadows for most, yet its persistent, unwelcome encore performances can range from a mild nuisance to a life-alvering ordeal for those it chooses to torment.
04 · Category
Transmission and Risk Factors25 stats
01
The probability of HSV-2 transmission from infected male to female per act of vaginal sex is 10% without condoms
02
Female-to-male HSV-2 transmission risk per vaginal sex act is approximately 4-5%
03
Condom use reduces HSV-2 transmission by 30-50% in discordant couples
04
HSV-2 shedding occurs on 15-30% of days in asymptomatic infected individuals
05
Acquisition of HSV-2 doubles the risk of HIV infection, with relative risk of 2.7 in women
06
Circumcision reduces HSV-2 incidence by 28-34% in men in randomized trials
07
Antiviral therapy like valacyclovir reduces HSV-2 transmission by 48% in discordant couples
08
HSV-2 transmission risk is highest during symptomatic outbreaks, up to 20-50% per contact
09
Oral HSV-1 confers 40-50% protection against HSV-2 genital acquisition
10
Number of sexual partners increases HSV-2 risk; OR 1.8 per additional partner lifetime
11
HSV-2 transmission from mother to neonate occurs in 1-3% of deliveries with maternal infection
12
Asymptomatic shedding accounts for 70% of HSV-2 transmissions
13
HIV-positive individuals have 2-3 fold higher HSV-2 shedding rates
14
Anal sex increases HSV-2 acquisition risk by 2-fold compared to vaginal sex
15
Spermicides containing nonoxynol-9 do not reduce HSV-2 transmission and may increase risk
16
Low socioeconomic status is associated with 1.5-2.0 OR for HSV-2 seropositivity
17
History of other STIs like chlamydia increases HSV-2 risk by OR 2.1
18
Smoking is linked to higher HSV-2 seroprevalence, OR 1.4 in women
19
HSV-2 transmission risk per year in discordant couples without intervention is 5-10% female-to-male
20
Black race/ethnicity associated with 3-4 fold higher HSV-2 prevalence after adjusting for confounders
21
Early age of sexual debut (<16 years) increases HSV-2 risk by OR 1.6
22
Suppressive acyclovir reduces plasma HIV viral load by 0.25 log10 copies/mL in co-infected individuals
23
Dental dams reduce transmission risk during oral-genital contact by 50-70%
24
HSV-2 shedding frequency decreases over time post-infection, from 30% to 10% of days after 10 years
25
Partner notification reduces transmission by identifying 20-30% undiagnosed cases
Interpretation
Transmission and Risk Factors Interpretation
Nature's frustrating design: a virus that often sheds invisibly and spreads with unsettling efficiency, but whose risks—while alarmingly interconnected with other diseases like HIV—can be significantly hacked down by a combination of condoms, medicine, and open communication.
05 · Category
Treatment, Management, and Prevention21 stats
01
Acyclovir 400mg three times daily for 7-10 days shortens primary outbreak duration by 2-4 days
02
Suppressive valacyclovir 500mg daily reduces recurrences by 70-80% in frequent shedders
03
Episodic acyclovir 800mg three times daily x 2 days aborts 40% of prodromal outbreaks
04
Famciclovir 250mg twice daily for 3 days treats recurrences as effectively as 5 days
05
Vaccine candidate HSV529 induces 65% reduction in HSV-2 acquisition in animal models
06
Daily suppressive therapy halves HIV transmission risk in HSV-2/HIV co-infected (Partners study)
07
Foscarnet 40mg/kg IV q8h for acyclovir-resistant HSV-2 in immunocompromised
08
Tenofovir gel reduces HSV-2 acquisition by 51% in women (CAPRISA 004)
09
Counseling on disclosure reduces transmission by 50% via abstinence during shedding
10
Laser therapy ablates lesions but does not reduce recurrence frequency
11
Pregabalin 150-300mg/day relieves post-herpetic neuralgia in 30-50% of chronic cases
12
Neonatal HSV-2 mortality 30% with dissemination despite IV acyclovir 60mg/kg/day x21 days
13
Pritelivir (phase 3) reduces shedding by 87% vs placebo in suppressive trials
14
Topical docosanol 10% shortens cold sore duration by 18 hours (OTC)
15
Male circumcision + condoms + suppressive therapy >90% effective preventing transmission
16
mRNA-1608 vaccine (Moderna) prevents HSV-2 disease in 100% guinea pigs preclinical
17
Lidocaine 5% patches alleviate lesion pain in 60% of patients during outbreaks
18
Sertraline for HSV-related depression improves quality of life in 40% (adjunctive)
19
No benefit from lysine supplementation >1g/day for recurrence prevention (meta-analysis)
20
C-section reduces neonatal transmission to <1% if mother has active lesions at delivery
21
RVx-201 therapeutic vaccine reduces shedding by 60% in phase 1/2 trials
Interpretation
Treatment, Management, and Prevention Interpretation
While we have an impressive arsenal of tools to suppress, treat, and prevent HSV-2—from daily pills that slash transmission risks to vaccines on the horizon—the sobering reality is that we’re still managing a persistent adversary, not yet achieving a cure.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Samuel Norberg. (2026, February 13). Hsv 2 Statistics. Gitnux. https://gitnux.org/hsv-2-statistics
MLA
Samuel Norberg. "Hsv 2 Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/hsv-2-statistics.
Chicago
Samuel Norberg. 2026. "Hsv 2 Statistics." Gitnux. https://gitnux.org/hsv-2-statistics.
Sources & references
12 datasets cited across this report · attribution is report-level